What Avasart HCT Treats: Main Uses and Benefits

Avasart HCT is a combination medication applied across domains where additional symptomatic support is needed, primarily for the treatment of hypertension (high blood pressure). It is commonly used across conditions presenting with acute episodes. It may be part of symptomatic management in patients whose blood pressure is not adequately controlled on monotherapy or may assist as initial therapy for those likely to require multiple medications.

The combination is applied in addressing symptoms related to systemic imbalance and heightened physiological activity. This supportive symptomatic management contributes to easing the overall symptom burden. This is relevant for easing the physiological strain and supporting general stability in the context of conditions involving episodic or fluctuating manifestations.

“This supportive symptomatic management contributes to easing the overall symptom burden.”

The medication assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Heightened Physiological Activity

Regulatory References

1. NIH DailyMed drug label for the combination

Avasart HCT is strictly restricted to certain adult populations and is contraindicated for several key groups.

Populations for Whom Use is Contraindicated

Use is contraindicated (absolutely prohibited) for women who are in the second or third trimesters of pregnancy due to the risk of fetal injury or death. It is also contraindicated for patients with anuria, severe hepatic impairment (liver failure), or severe renal impairment (kidney disease, typically GFR < 30 mL/min). Absolute contraindications also apply to individuals with known hypersensitivity to the active ingredients (Valsartan, Hydrochlorothiazide) or any sulfonamide-derived drugs.

Age-Related and Conditional Eligibility

Eligibility is generally established for adults with hypertension whose blood pressure requires combination therapy. However, the medicine is not recommended for children and adolescents under 18 years old, as safety and efficacy data are not established in this population. Use is also not recommended for women who are breastfeeding. Special caution is indicated for patients with conditions like aortic or mitral valve stenosis or a history of systemic lupus erythematosus. In the event pregnancy is detected in the first trimester, the medicine must be discontinued immediately.

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Avasart HCT (Valsartan/Hydrochlorothiazide) as described in regulatory prescribing information.

Pharmacodynamic and Exposure-Altering Interactions

Co-administration with certain substances is documented to alter the safety profile or systemic exposure of Avasart HCT's active components:

• Agents Increasing Serum Potassium: Combination with substances such as potassium-sparing diuretics (e.g., spironolactone) or potassium supplements is officially documented to increase the risk of hyperkalemia (high serum potassium).
• Lithium: The combination may reduce the renal clearance of Lithium, which can lead to a documented increase in the risk of lithium toxicity.
• Other Antihypertensive Agents: Co-administration with other blood pressure-lowering medications may result in an additive or potentiating effect, increasing the risk of symptomatic hypotension.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): These are documented to reduce the diuretic, natriuretic, and antihypertensive effects of Avasart HCT. This co-administration also carries a heightened risk of renal function deterioration in specific populations, such as elderly or volume-depleted patients.

Contraindicated and Transporter-Mediated Interactions

• Contraindicated Combination: The co-administration of Aliskiren is contraindicated in patients with diabetes due to the officially recognized risks associated with dual blockade of the Renin-Angiotensin System (RAS).
• Transporter Inhibitors: Specific agents, including Rifampin, Cyclosporine, and Ritonavir, are documented to increase the systemic exposure of Valsartan by inhibiting its uptake or efflux transporters.
• Timing Requirement: To minimize the reduction in Hydrochlorothiazide absorption, it must be administered at least 4 hours before or 4–6 hours after anion exchange resins, such as Cholestyramine or Colestipol.

Avasart HCT is a combination of an Angiotensin II Receptor Blocker (ARB) and a diuretic. The ARB component functions as an antagonist by blocking the binding of angiotensin II to the AT1 receptor in tissues. This receptor antagonism prevents the vasoconstrictive effects of angiotensin II, which results in the dilation of blood vessels. The second component, hydrochlorothiazide (HCT), is a thiazide diuretic. It works by inhibiting the Na^+Cl^- cotransporter located in the luminal membrane of the distal convoluted tubule of the kidney. This inhibition decreases the reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes. Together, these two mechanisms modulate the Renin-Angiotensin-Aldosterone System (RAAS) and increase diuresis.

How to Use Avasart HCT: Official Administration Guidelines

Administration Scope

Avasart HCT is strictly for oral administration only, in the form of a fixed-dose combination tablet. The tablets should be swallowed whole with water. The medicine is generally administered once daily and can be taken with or without food, providing flexibility in daily intake. To maintain consistency in long-term maintenance therapy, it is often suggested to take the dose at the same time each day.

Official Dosing and Scheduling

The typical starting dose for adults, particularly when used as add-on therapy for uncontrolled hypertension or as initial therapy likely requiring multiple agents, is 160 mg / 12.5 mg (Valsartan/HCTZ) once daily. The maximum recommended daily dose is 320 mg / 25 mg. Dosage adjustments are typically assessed after 1 to 2 weeks of therapy, which aligns with the clinical observation that the maximum antihypertensive effect following a dose change is usually attained within 2 to 4 weeks.

Population and Procedural Constraints

Official instructions detail constraints for specific populations. The medicine is not recommended for use in patients with severe renal impairment (creatinine clearance leq 30 mL/min) or for patients under the age of 18. While no initial dose adjustment is required for older adults, patients with mild to moderate hepatic impairment should not exceed the 80 mg dose of the Valsartan component. If a dose is missed, instructions advise that the missed dose should be skipped if the next scheduled dose is near; users should not take two doses to compensate and should resume their regular once-daily schedule.

Research Evidence / Overview of Studies for Avasart HCT

Evidence for Use in Managing High Blood Pressure

Research examining the use of Avasart HCT (Valsartan/Hydrochlorothiazide) has predominantly utilized Randomized Controlled Trials (RCTs). This research explored studies focusing on the condition of essential high blood pressure in adults whose condition was not adequately addressed by taking a single medication alone.

The main focus of these studies was to monitor and measure changes in blood pressure. Researchers monitored both the Systolic Blood Pressure (SBP) (the top number) and the Diastolic Blood Pressure (DBP) (the bottom number). Findings describe the patterns of measured shifts in these blood pressure numbers reported for participants receiving the combination therapy. Studies also reported the calculated percentage of participants who achieved a pre-defined blood pressure measurement during the short-term study period. The duration of most pivotal studies was short- to intermediate-term, typically ranging from a few weeks up to about four months.

How the Combination Was Studied Against Other Treatments

Research explored the evaluation of the combination therapy compared with a placebo or with the use of the single ingredients alone. Studies explored short-term changes in blood pressure readings. These controlled trials were used to establish the measured differences in blood pressure between the combination and the individual agents (Valsartan or Hydrochlorothiazide) in the observed populations.

Research described patterns of blood pressure measurements observed when participants received the combination, compared to those receiving the single components or placebo. Studies described patterns related to outcomes reflecting physiological strain.

Understanding the Research Gaps and Uncertainties

Limited information is available for patients under the age of 18, as the research primarily focused on adult populations. Additionally, comparative evidence is lacking or findings were mixed for some very high-risk patient subgroups, meaning the data are still emerging and certainty remains low in these specific groups.

A key limitation of the available research, noted in official documents, is that the primary studies focused on blood pressure reduction. This is a surrogate measure—meaning it is a substitute measure rather than the final health outcome itself. There are no controlled trials specifically designed and powered to demonstrate that the use of Avasart HCT directly reduces the risk of fatal or nonfatal cardiovascular events, such as a heart attack or stroke.

Key Studies & References

1. FDA Approved Labeling for Diovan HCT (Valsartan and Hydrochlorothiazide) Tablets - Clinical Studies and Limitations

Common questions about Avasart HCT (FAQ)

Q: How is Avasart HCT different from taking Valsartan alone?

A: Avasart HCT is a combination of two active medicines: Valsartan (an Angiotensin II Receptor Blocker) and Hydrochlorothiazide (a thiazide diuretic). The combination provides a dual action that is commonly used to achieve sustained blood pressure control, which is often greater than achieved with the individual components alone. The Valsartan component helps relax blood vessels, while the Hydrochlorothiazide component helps the kidneys manage unneeded salt and water.

Q: Are there special considerations for older adults using Avasart HCT?

A: Regulatory information notes that exposure to the Valsartan component is higher and its half-life is longer in older adults. While no initial dose adjustment is typically specified for older adults, official guidance recommends that monitoring of kidney function and potassium levels may be appropriate. This is due to the increased susceptibility of older patients to certain conditions like renal impairment.

Q: Is Avasart HCT classified as a blood thinning medicine or anticoagulant?

A: Official classification identifies this medicine as an Angiotensin II Receptor Blocker (ARB) and a thiazide diuretic. These are a type of medicine used to manage high blood pressure (antihypertensive agents). It is not classified as a blood thinning medicine or anticoagulant.

Q: What is the research evidence for Avasart HCT regarding heart health benefits?

A: The general purpose of lowering high blood pressure with this medicine is to support the reduction of cardiovascular risk. Official documents describe that reducing high blood pressure is associated with a reduction in the risk of events such as strokes and myocardial infarctions (heart attacks).

Q: Are there any general restrictions on driving or operating machinery while taking Avasart HCT?

A: Because this medicine may cause common side effects like dizziness or syncope (fainting), regulatory safety information includes warnings about caution. Due to these potential effects, official guidance notes that people may need to take care when performing tasks that require full attention, such as driving or operating machinery.

Q: Is Avasart HCT used for treating conditions other than high blood pressure?

A: Official documents primarily indicate the use of this combination tablet for the treatment of high blood pressure (hypertension). No other indications for the specific combination of Valsartan and Hydrochlorothiazide are listed in the FDA prescribing information.

Q: What exactly does the 'HCT' part of Avasart HCT stand for?

A: The abbreviation HCT stands for the diuretic component contained within the tablet. This component is Hydrochlorothiazide.

Q: Is Avasart HCT similar to other ARB medicines?

A: The Valsartan component of the medicine belongs to a class of drugs known as Angiotensin II Receptor Blockers (ARBs). All medicines in this class share a similar mechanism of action: they work by blocking the binding of Angiotensin II to its receptor in the body.

Q: Can Avasart HCT cause swelling in the hands or feet?

A: The official safety profile for the components of this medicine includes reports of swelling in the hands or feet as a potential side effect. This type of swelling is listed as a possible adverse reaction.

Q: Is it necessary to limit salt intake while using this medicine?

A: Management of high blood pressure often involves lifestyle changes alongside medication. Official regulatory sources note that for blood pressure treatment, changes in the types of foods eaten, especially those high in sodium (salt), may be considered to support the medicine's effect.

Q: Are there any known interactions between Avasart HCT and alcohol consumption?

A: Regulatory documents state that the combination of this medicine with alcohol may lead to a potentiation, or increase, of a condition called orthostatic hypotension. This refers to a drop in blood pressure that can occur when standing up.

Q: Is Avasart HCT intended for long-term or short-term treatment?

A: The treatment of high blood pressure is typically a long-term commitment. For maintenance therapy, the medicine is designed to be continued under the guidance of a healthcare provider.

Q: Does Avasart HCT require regular blood tests or monitoring?

A: Regulatory guidance describes that monitoring of renal function (how well the kidneys are working) and potassium levels is necessary in susceptible patients. This is due to the potential effects of the medicine on the body's electrolytes and kidney function.

Q: Is there a risk of increased sun sensitivity while taking Avasart HCT?

A: The Hydrochlorothiazide component is associated with an increased risk of sensitivity to UV rays from both sunlight and tanning lamps. Official warnings also note that long-term use of Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer.

Q: Can Avasart HCT affect blood sugar levels?

A: The Hydrochlorothiazide component may cause an increase in blood sugar (glucose) levels. Dosage adjustments for antidiabetic medication may be necessary in some cases.

Q: What regulatory agencies have officially approved Avasart HCT for use?

A: Official approval for this medicine has been granted by government regulatory bodies in various regions. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), among other national health authorities.

The official regulatory documents define mandatory conditions for the storage and disposal of Avasart HCT (valsartan and hydrochlorothiazide) tablets to maintain product quality.

Required Storage and Protection

The medication must be stored at Controlled Room Temperature, which is formally 20 C to 25 C (68 F to 77 F). Permitted temperature excursions extend from 15 C to 30 C.

For container and product stability, the tablets must be stored in the original container and kept tightly closed to protect them from environmental elements. The medication must be kept out of the reach of children.

Official Disposal

Unused or outdated Avasart HCT must be discarded. Disposal of the product should be conducted strictly according to local regulations for pharmaceutical waste.